The independent source for health policy research, polling, and news.
Showing 21 - 40 of 117
Xlear, a maker of xylitol gum, has sued the Federal Trade Commission, saying the onus should be on government to prove that ingredients donāt live up to advertised claims. RFK Jr.ās āmedical freedomā allies have rallied to the cause.
After spearheading a 34% cut in cancer mortality, the National Cancer Institute at the NIH is bleeding resources and staff and could see its budget cut by nearly 40%.
A new vaccine advisory panel appointed by the HHS secretary, a longtime anti-vaccine activist, reflected his unsupported claims about the safety of childhood inoculations.
Vaccines are under fire from the top of the Trump administration. Federal programs to monitor them and make them safer have always been underfunded.
Worried that President Donald Trumpās FDA might not act, a panel of cancer experts recommended that doctors consider testing before dosing patients with a commonly used but sometimes deadly cancer drug. It came too late for many patients.
While Big Pharma seems ready to weather the tariff storm, independent pharmacists and makers of generic drugs ā which account for 90% of U.S. prescriptions ā see trouble ahead for patients.
Secretary Robert F. Kennedy Jr.ās HHS said an enormous, noncompetitive flu vaccine development grant to two favored NIH leaders would ensure ātransparency, effectiveness, and comprehensive preparedness.ā But their vaccine is in early stages, relies on old technology, and is just one of scores of similar efforts.
Attitudes about a debunked link between measles vaccines and autism havenāt budged that much. But thereās a sharp partisan divide over whether the vaccine is safe.
Recent cuts eliminated a small, specialized workforce that sets the poverty standards determining who is eligible for Medicaid as well as assistance with food, home heating, child care, and more.
The Agency for Healthcare Research and Quality has helped improve health care safety in a country where thousands die of medical errors each year. It was effectively dissolved Tuesday.
Two senior scientists say National Institutes of Health officials advised them to remove references to mRNA vaccines in grant applications, and they fear the Trump administration will abandon a promising field of medical research.
Should Marty Makary take the reins at the FDA, transitioning from gadfly to the head of an agency that regulates a fifth of the U.S. economy, he would have to engage in the thorny challenges of governing.
The FDA is already limited in policing claims of health benefits by makers of supplements and herbal remedies ā a $70 billion industry. Get ready for even less regulation.
Jay Bhattacharya, nominated to lead the National Institutes of Health, opposed most covid mandates. Without an honest public debate about what worked and what didnāt, public health experts say, weāre even less prepared for the next pandemic.
Two Senate committees are expected to question Robert F. Kennedy Jr. on how his disproven views of science and medicine qualify him to run the $1.7 trillion, 80,000-employee federal health system.
As criticism of pharmacy benefit managers heats up, fear of lawsuits is driving some big employers to drop the āBig Threeā PBMs ā or force them to change.
Inoculation campaigns that protect children and adults from dangerous diseases rely on a delicate web of state and federal laws and programs. If senior officials cast doubt on vaccine safety, the whole system might collapse, especially in red states.
As federal health scientists await a potential takeover by RFK Jr. and other medical skeptics in the second Trump administration, some are preparing rƩsumƩs or retirement papers.
Health care has ebbed and surged as an election issue throughout the presidential campaign. Here are the ways some of the most consequential changes in health policies could hinge on whether Vice President Kamala Harris or former President Donald Trump wins.
Stay informed by signing up for the Morning Briefing and other emails:
Ā© 2026 KFF